Loading...
Market
What will be the market share of VOQUEZNA in GERD treatment by December 31, 2024?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Market research reports and sales data
Story
Phathom Pharmaceuticals Receives FDA Approval for VOQUEZNA for GERD Heartburn Relief in Adults
Jul 18, 2024, 12:04 PM
Phathom Pharmaceuticals has received FDA approval for its drug VOQUEZNA (vonoprazan) tablets. The medication is intended for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. This approval, announced on July 17 and July 18, marks a significant milestone for Phathom Pharmaceuticals, which has a short interest of over 40%. VOQUEZNA is a potassium-competitive acid blocker (PCAB), expanding its approval to cover more GERD patients.
View original story
Similar markets
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Increase by less than 5% • 33%
Increase by 5% to 10% • 34%
Increase by more than 10% • 33%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%